Privanova

Advancing Diagnosis and Management of Psychiatric Symptoms in Mental Disorders and Neurodegenerative Diseases

Challenge

Mental disorders (MDs), such as depression and schizophrenia, and neurodegenerative disorders (NDs), like Alzheimer's disease, share a common thread: disrupted connections within the brain. This leads to overlapping emotional, behavioural, and cognitive symptoms. Unfortunately, current treatments like antidepressants and antipsychotics are often ineffective for ND patients and many individuals with MDs develop treatment resistance. This lack of effective treatment options creates a significant burden on patients, their families, and society as a whole. The Synapsing project aims to tackle this challenge by creating a comprehensive database of clinical, neuroimaging, and socioeconomic data from over 3000 patients across Europe. This will provide valuable insights into the shared mechanisms underlying these conditions and pave the way for improved diagnosis and treatment strategies.

Objectives

To achieve its goals, SYNAPSING will pursue a multi-faceted approach. This includes developing blood-based biomarkers for faster and more accurate diagnosis, distinguishing between MDs and NDs, and predicting treatment response. By utilising post-mortem brain tissue and stem cell models, researchers will delve into the biological mechanisms of synapse dysfunction. Furthermore, the project will investigate the influence of socioeconomic factors on mental health, ultimately providing evidence-based policy recommendations to reduce disparities in access to care and improve overall mental well-being. The expected outcomes of SYNAPSING include a deeper understanding of these complex disorders, refined clinical guidelines for diagnosis and management, and strengthened knowledge and care networks across Europe.

Our Role

Privanova will play a critical role in ensuring the ethical integrity of the SYNAPSING project. They will be responsible for interpreting and implementing any ethical requirements from the European Commission, translating them into clear guidelines for all partners to follow. This includes delivering a report with recommendations to introduce policies to reduce social disparities related to mental health issues, establishing an Ethics Advisory Board with both internal and external experts to provide oversight and guidance on ethical and social issues related to the project, with Privanova leading the consortium's contribution to the board. Throughout the project's lifespan, Privanova will champion responsible research and innovation, ensuring compliance with the applicable ethical standards and data protection regulations. Privanova will also contribute to developing synergies with the research and clinical community from the MD and ND fields by organising the SynergyHealth cluster workshop.

 

                                 

Call

Call ID

HORIZON-HLTH-2024-DISEASE-03-two-stage

Grant ID

Grant ID

101156566

Duration

Duration

January 2025 - December 2029

Budget

Budget

€ 6 999 921.91

Get the Project Factsheet

Download PDF

Consortium

  • Sant Pau Research Institute Sant Pau Research Institute
  • PRIVANOVA SAS PRIVANOVA SAS
  • Neoventures Biotechnology Europe Neoventures Biotechnology Europe
  • University of Eastern Finland University of Eastern Finland
  • NMI Natural and Medical Sciences Institute NMI Natural and Medical Sciences Institute
  • University of the Basque Country  University of the Basque Country
  • MQ Mental Health Research MQ Mental Health Research
  • GRANTXPERT CONSULTING LIMITED GRANTXPERT CONSULTING LIMITED
  • ADX NEUROSCIENCES ADX NEUROSCIENCES
  • University of Gothenburg University of Gothenburg
  • Ulm University  Ulm University
  • University of Perugia University of Perugia
  • Martin Luther University Halle-Wittenberg Martin Luther University Halle-Wittenberg

Question about this project?

Contact us